The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10717753 B1

Date of Patent:

Jul. 21, 2020

Filed:

Nov. 24, 2016

Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof

Applicant:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang, CN;

Inventors:

Yinsheng Zhang, Lianyungang, CN;

Baomin Liu, Lianyungang, CN;

Beibei Yang, Lianyungang, CN;

Assignee:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang, CN;

Attorney:

Nixon Peabody LLP

Primary Examiner:

Joseph R Kosack

Int. Cl.

CPC ...

C07F 9/6558 (2006.01); A61K 31/675 (2006.01); A61P 35/00 (2006.01); C07B 59/00 (2006.01);

U.S. Cl.

CPC ...

C07F 9/65583 (2013.01); A61K 31/675 (2013.01); A61P 35/00 (2018.01); C07F 9/6558 (2013.01); C07B 59/004 (2013.01);

Abstract

The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

Find Patent Forward Citations

Zhang, Yinsheng. (2020). Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof (U.S. Patent No. 10717753). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10717753

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile